Manufacturing Day at Novonesis Tue Micheelsen, President, Novonesis North America and Carolyn Lee, President & Executive Director of the Manufacturing Institute accompany students on a Novonesis tour at the MFG Day event. Manufacturing Day at Novonesis Students engage with education partners at Novonesis at the MFG Day event. Franklinton, NC, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Novonesis, a global leader in biosolutions, welcomed hundreds of local students, educators, and community leaders to its faci ...

Core Technology & Scientific Advancements - The industry is at the cusp of programming life by understanding and manipulating cells like sophisticated software [5][6] - Systems biology offers a holistic approach to reprogramming life by mapping molecular interactions within cells, similar to a city-wide traffic map, to identify bottlenecks in disease networks [7][8] - Genetically Encoded Metabolic Manipulators and Sensors (GEMS) are DNA-based living therapies that act as molecular smoke detectors to restore balance in cancer cells [13] - Synthetic biology tools, like CRISPR, enable modular design of living therapies, allowing for rapid updates and adaptive defense strategies against diseases [14] Applications & Bioeconomy - Synthetic biology can be applied to create sustainable biofactories for producing fuels, food flavors, and materials from renewable resources, reducing reliance on fossil fuels and carbon emissions [19] - Microbial strains can be engineered to produce valuable compounds like violacein (a purple pigment with antimicrobial properties) and vanillin (vanilla flavor), as well as biodegradable plastics [20][21] - Synthetic biology is rewriting product design and rebuilding global supply chains, potentially impacting various industries from toothpaste to pharmaceuticals [23] Ethical Considerations & Future Implications - Advances in genetic engineering raise ethical questions about genetic personalization, designer babies, and the potential for exacerbating social inequalities [25] - The industry emphasizes the need for public awareness, open dialogue, and responsible governance to navigate the ethical implications of programming life [26] - The industry is at the dawn of a biological renaissance, with DNA as the code and humanity as the storytellers, holding the power to program life itself [28]

Core Insights - Infortar's sales volumes increased significantly in Q2 2025, reaching €505 million, a 150% increase compared to the previous year [1] - The company successfully acquired Estonia Farmid, enhancing its position in the agricultural sector and contributing to the bioeconomy [2] - Infortar invested €38 million in various projects, including renewable energy initiatives and infrastructure developments [3] Sales and Financial Performance - In the first half of 2025, Infortar's consolidated revenue rose by €275.73 million to €951.869 million, largely due to the consolidation of Tallink Grupp's results [11] - The EBITDA for the energy segment improved to €19.929 million in Q2 2025, compared to a loss of €0.845 million in Q2 2024 [13] - The consolidated net loss for the first half of 2025 was €-14.4 million, a significant decline from a net profit of €73.017 million in the same period of 2024 [14] Segment Performance - The maritime transport segment saw an increase in passenger numbers to 1,488,128, a 2.5% rise from Q2 2024, while cargo units transported decreased by 22.8% [4] - The energy segment's gas and electricity sales reached 4.9 TWh, a 25% increase year-over-year, with a market share of 27.7% in the Finnish-Baltic market [6] - In real estate and infrastructure, Infortar completed the Pärnu bridge and continued work on the Rail Baltica mainline, valued at €67.2 million [7] Investments and Projects - Infortar's investments in the first half of 2025 totaled approximately €38 million, focusing on renewable energy and infrastructure projects [15] - The company is constructing one of Estonia's largest biomethane plants and a new solar power plant in Latvia [3] Financial Position - As of June 30, 2025, Infortar's total liabilities amounted to €941.747 million, with net debt at €795.379 million [16] - The net debt to EBITDA ratio was reported at 3.4, indicating the company's leverage position [16] Dividends - Infortar plans to pay a dividend of €3 per share for the 2024 financial year, with the first payment made on July 15, 2025 [17]